QUAGLINO, Pietro

QUAGLINO, Pietro  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 20 di 607 (tempo di esecuzione: 0.024 secondi).
Titolo Data di pubblicazione Autore(i) File
1975-2011 Overall Survival, Disease Free Survival and Survival after Recurrence across gender in melanoma patients: what has changed? 2012 Simone Ribero; Pietro Quaglino; Martina Sanlorenzo; Simona Osella-Abate; Federica Marenco; Tiziana Nardò; Giuseppe Macripò; Maria Teresa Fierro; Maria Grazia Bernengo
262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study 2017 Kim, Y.H.; Whittaker, S.; Horwitz, S.M.; Duvic, M.; Dummer, R.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Wang, Y.; Palanca-Wessels, M.; Zagadailov, E.; Trepicchio, W.L.; Lin, H.; Little, M.; Prince, H.
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 2011 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
A simple scoring system for the diagnosis of palmo-plantar pigmented skin lesions by digital dermoscopy analysis. 2012 Rubegni P; Cevenini G; Nami N; Argenziano G; Saida T; Burroni M; Quaglino P; Bono R; Hofmann-Wellenhof R; Fimiani M.
A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides. 2014 Ferrara G; Pancione M; Votino C; Quaglino P; Tomasini C; Santucci M; Pimpinelli N; Cusano F; Sabatino L; Colantuoni V.
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies 2017 Sanlorenzo, Martina; Vujic, Igor; Floris, Arianna; Novelli, Mauro; Donini, Chiara; Gammaitoni, Loretta; Giraudo, Lidia; Macagno, Marco; Quaglino, Pietro; Fierro, Maria Teresa; Giordano, Silvia; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario
Activity and safety of bexarotene as maienance therapy in CTCL patients with stable disease or remission after systemic treatments: a prospective multicenter trial from the GILC 2011 Quaglino P
Activity and safety of bexarotene as maintainance therapy in advanced/aggressive CTCL patients with stable disease or remission after systemic treatment: an observational multicenter trial from the GILC 2007 Pietro Quaglino; Maria Grazia Bernengo
Activity and safety of Bexarotene as maintenance therapy in CTCL patients (Mycosis Fungoides stage IIB-IV, Sezary Syndrome, peripheral T-cell lymphoma) with stable disease or remission after systemic treatments: A prospective multicenter trauil from the Italian Group of Cutaneous Lymphoma (GILC) 2011 Quaglino P;Pimpinelli N; Alaibac M; Quintini G; Bernengo MG
Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era 2021 Avallone, Gianluca; Astrua, Chiara; Fava, Paolo; Tonella, Luca; Mastorino, Luca; Agostini, Andrea; Merli, Martina; Rubatto, Marco; De Pasquale, Rocco; Conti, Luca; Quaglino, Pietro; Ribero, Simone
Acute digital gangrene in a long-term dialysis patient -- a diagnostic challenge. 2002 PICCOLI GB; QUAGLIA M; QUAGLINO P; BURDESE M; BERMOND F; MEZZA E; JEANTET A; SEGOLONI GP
Adalimumab for the treatment of pediatric psoriasis: a single center experience of 4 cases 2019 Licciardello, Matteo; Arese, Veronica; Panzone, Michele; Dapavo, Paolo; Ribero, Simone; Fierro, Maria Teresa; Quaglino, Pietro
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 2021 Eggermont A.M.M.; Blank C.U.; Mandala M.; Long G.V.; Atkinson V.G.; Dalle S.; Haydon A.M.; Meshcheryakov A.; Khattak A.; Carlino M.S.; Sandhu S.; Larkin J.; Puig S.; Ascierto P.A.; Rutkowski P.; Schadendorf D.; Koornstra R.; Hernandez-Aya L.; Di Giacomo A.M.; van den Eertwegh A.J.M.; Grob J.-J.; Gutzmer R.; Jamal R.; Lorigan P.C.; van Akkooi A.C.J.; Krepler C.; Ibrahim N.; Marreaud S.; Kicinski M.; Suciu S.; Robert C.; Menzies A.; Lesimple T.; Maio M.; Linette G.; Brown M.; Hersey P.; Svane I.M.; Mortier L.; Schachter J.; Barrow C.; Kudchadkar R.; Song X.; Dutriaux C.; Quaglino P.; Meier F.; Queirolo P.; Stroyakovskiy D.; Bastholt L.; Guillot B.; Garbe C.; Ortiz Romero P.L.; Grange F.; Mohr P.; Algazi A.; Bechter O.; Hernberg M.; Arnault J.-P.; Saiag P.; Loquai C.; Meiss F.; Simon J.-C.; Bar-Sela G.; Chiarion Sileni V.; Fitzharris B.; McCrystal M.; Parente P.; Baurain J.-F.; Combemale P.; Lebbe C.; Hauschild A.; Yamazaki N.; Dummer R.; Milhem M.; Dzienis M.; Walker J.; Geoffrois L.; Leccia M.-T.; Kretschmer L.; Hendler D.; Lotem M.; Mackiewicz A.; Sekulovic L.; Dunwoodie E.; Hoeller C.; Machet L.; Hassel J.; Hospers G.A.P.; Passos M.-J.; Levin M.; Fehr M.; Corrie P.; Waterston A.; Hallmeyer S.; Schmidt H.; Descamps V.; Lacour J.-P.; Berking C.; Kiecker F.; Ferrucci P.F.; Yokota K.; Aarts M.; Jameson M.; Winge-Main A.K.; Ferreira P.; Kim K.; McNeil C.; Hofmann-Wellenhof R.; Kerger J.; Aubin F.; Utikal J.; Ferraresi V.; Inozume T.; Kiyohara Y.; Groenewegen G.; Kapiteijn H.; Matkovic S.; Boehncke W.-H.; Casasola R.; Crook T.; Marshall E.; Skytta T.; Avril M.-F.; Jouary T.; Hein R.; Terheyden P.; Aoi J.; Takenouchi T.; Straume O.; Martins C.; Mukhametshina G.; Nathan P.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial 2021 Bottomley A.; Coens C.; Mierzynska J.; Blank C.U.; Mandala M.; Long G.V.; Atkinson V.G.; Dalle S.; Haydon A.M.; Meshcheryakov A.; Khattak A.; Carlino M.S.; Sandhu S.; Puig S.; Ascierto P.A.; Larkin J.; Lorigan P.C.; Rutkowski P.; Schadendorf D.; Koornstra R.; Hernandez-Aya L.; Di Giacomo A.M.; van den Eertwegh A.J.M.; Grob J.-J.; Gutzmer R.; Jamal R.; van Akkooi A.C.J.; Krepler C.; Ibrahim N.; Marreaud S.; Kicinski M.; Suciu S.; Robert C.; Eggermont A.M.M.; Lesimple T.; Maio M.; Linette G.; Mortier L.; Svane I.M.; Schachter J.; Brown M.; Hersey P.; Barrow C.; Kudchadkar R.; Dutriaux C.; Song X.; Quaglino P.; Queirolo P.; Meier F.; Stroyakovskiy D.; Guillot B.; Romero P.L.O.; Bastholt L.; Garbe C.; Grange F.; Mohr P.; Algazi A.; Bechter O.; Hernberg M.; Loquai C.; Meiss F.; Chiarion Sileni V.; Bar-Sela G.; Fitzharris B.; Saiag P.; Arnault J.-P.; Simon J.-C.; Stephens R.; Baurain J.-F.; Lebbe C.; Combemale P.; Dummer R.; Hauschild A.; Parente P.; Yamazaki N.; Milhem M.; Leccia M.-T.; Geoffrois L.; Kretschmer L.; Dunwoodie E.; Walker J.; Lotem M.; Hendler D.; Mackiewicz A.; Sekulovic L.; Dzienis M.; Hospers G.A.P.; Siano M.; Hassel J.; Corrie P.; Passos M.-J.; Levin M.; Hoeller C.; Machet L.; Hallmeyer S.; Waterston A.; Descamps V.; Kiecker F.; Aarts M.; Schmidt H.; Raimundo A.; Nyakas M.; Lacour J.-P.; Berking C.; Ferrucci P.F.; Jameson M.; Kim K.; Yokota K.; Kerger J.; Aubin F.; Groenewegen G.; Kapiteijn H.; Boehncke W.-H.; Utikal J.; Casasola R.; Marshall E.; Ferraresi V.; Richtig E.; Matkovic S.; Inozume T.; Crook T.; McNeil C.; Kiyohara Y.; Avril M.-F.; Hein R.; Terheyden P.; Nathan P.; Aoi J.; Skytta T.; Jouary T.; Takenouchi T.; Straume O.; Martins C.; Mukhametshina G.
Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance 1995 DOVEIL GC; FIERRO MT; M. NOVELLI; APPINO A; BERTERO M; QUAGLINO P; BERNENGO MG
Adult-onset cutaneous mastocytosis in monozygotic twins. 2011 Quaglino P; Mola F; Peroni A; Ortoncelli M; Di Bello C; Savoia P; Bernengo MG
After Surgery: Follow-Up Guidelines of Melanoma Patients 2013 Paolo Fava; Pietro Quaglino; Maria Grazia Bernengo; Paola Savoia
Aggressive subtypes of cutaneous T-cell lymphoma subsets: management and prognosis. 2003 BERNENGO M.G.; QUAGLINO P.
Alemtuzumab - low dose therapy schedule effective for CTCL 2011 Quaglino Pietro
Alemtuzumab for the treatment of Sézary sindrome: clinical and immunological findings in 10 patients. 2006 Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Fierro MT.